Raymond James & Associates’s Prestige Consumer Healthcare PBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $8.81M | Buy |
122,144
+4,342
| +4% | +$307K | 0.01% | 1301 |
|
|
2024
Q2 | $8.11M | Buy |
117,802
+10,823
| +10% | +$733K | 0.01% | 1286 |
|
|
2024
Q1 | $7.76M | Buy |
106,979
+6,334
| +6% | +$424K | 0.01% | 1299 |
|
|
2023
Q4 | $6.16M | Buy |
100,645
+4,212
| +4% | +$250K | ﹤0.01% | 1398 |
|
|
2023
Q3 | $5.52M | Buy |
96,433
+394
| +0.4% | +$23.8K | ﹤0.01% | 1399 |
|
|
2023
Q2 | $5.71M | Buy |
96,039
+31,216
| +48% | +$1.87M | ﹤0.01% | 1392 |
|
|
2023
Q1 | $4.06M | Buy |
64,823
+4,393
| +7% | +$274K | ﹤0.01% | 1604 |
|
|
2022
Q4 | $3.78M | Sell |
60,430
-1,992
| -3% | -$114K | ﹤0.01% | 1600 |
|
|
2022
Q3 | $3.11M | Buy |
62,422
+56,391
| +935% | +$3.12M | ﹤0.01% | 1695 |
|
|
2022
Q2 | $355K | Sell |
6,031
-3,295
| -35% | -$182K | ﹤0.01% | 3124 |
|
|
2022
Q1 | $494K | Buy |
9,326
+4,279
| +85% | +$247K | ﹤0.01% | 3084 |
|
|
2021
Q4 | $306K | Buy |
+5,047
| New | +$300K | ﹤0.01% | 3427 |
|
|
2020
Q3 | – | Sell |
-9,936
| Closed | -$373K | – | 3664 |
|
|
2020
Q2 | $373K | Sell |
9,936
-58,925
| -86% | -$2.36M | ﹤0.01% | 2798 |
|
|
2020
Q1 | $2.53M | Sell |
68,861
-9,746
| -12% | -$379K | ﹤0.01% | 1440 |
|
|
2019
Q4 | $3.18M | Sell |
78,607
-1,846
| -2% | -$68.9K | ﹤0.01% | 1544 |
|
|
2019
Q3 | $2.79M | Buy |
80,453
+63
| +0.1% | +$2.08K | ﹤0.01% | 1586 |
|
|
2019
Q2 | $2.55M | Sell |
80,390
-5,966
| -7% | -$177K | ﹤0.01% | 1650 |
|
|
2019
Q1 | $2.58M | Buy |
86,356
+23,856
| +38% | +$684K | ﹤0.01% | 1596 |
|
|
2018
Q4 | $1.93M | Sell |
62,500
-1,001
| -2% | -$36.5K | ﹤0.01% | 1684 |
|
|
2018
Q3 | $2.41M | Buy |
63,501
+18,338
| +41% | +$694K | ﹤0.01% | 1705 |
|
|
2018
Q2 | $1.73M | Buy |
45,163
+11,989
| +36% | +$404K | ﹤0.01% | 1850 |
|
|
2018
Q1 | $1.12M | Sell |
33,174
-11,775
| -26% | -$452K | ﹤0.01% | 2055 |
|
|
2017
Q4 | $2M | Sell |
44,949
-166
| -0.4% | -$7.56K | ﹤0.01% | 1693 |
|
|
2017
Q3 | $2.26M | Sell |
45,115
-268
| -0.6% | -$13.7K | ﹤0.01% | 1569 |
|
|
2017
Q2 | $2.4M | Buy |
45,383
+13,717
| +43% | +$735K | 0.01% | 1449 |
|
|
2017
Q1 | $1.76M | Buy |
31,666
+415
| +1% | +$22.9K | ﹤0.01% | 1602 |
|
|
2016
Q4 | $1.63M | Sell |
31,251
-1,017
| -3% | -$49.1K | ﹤0.01% | 1619 |
|
|
2016
Q3 | $1.56M | Buy |
32,268
+5,508
| +21% | +$279K | ﹤0.01% | 1612 |
|
|
2016
Q2 | $1.48M | Sell |
26,760
-12,873
| -32% | -$709K | ﹤0.01% | 1506 |
|
|
2016
Q1 | $2.12M | Sell |
39,633
-3,023
| -7% | -$149K | 0.01% | 1250 |
|
|
2015
Q4 | $2.2M | Buy |
42,656
+8,592
| +25% | +$427K | 0.01% | 1214 |
|
|
2015
Q3 | $1.54M | Sell |
34,064
-11,775
| -26% | -$556K | 0.01% | 1358 |
|
|
2015
Q2 | $2.12M | Buy |
45,839
+8,178
| +22% | +$358K | 0.01% | 1283 |
|
|
2015
Q1 | $1.61M | Sell |
37,661
-11,239
| -23% | -$428K | 0.01% | 1371 |
|
|
2014
Q4 | $1.7M | Buy |
+48,900
| New | +$1.62M | 0.01% | 1255 |
|
Other funds holding PBH
AI
Raymond James & Associates's PBH Position: Q3 2024 in Review
Raymond James & Associates increased its Prestige Consumer Healthcare (PBH) stake by 3.7% in Q3 2024, buying an estimated $307K and bringing the position to 122,144 shares worth $8.81M. The position accounts for 0.01% of the portfolio, ranked #1301.
Raymond James & Associates first reported a position in PBH in Q4 2014 and has held it in 35 quarters since. 328 funds tracked by Wall St. Rank hold PBH as of Q3 2024.
- Raymond James & Associates held 122,144 shares of Prestige Consumer Healthcare worth $8.81M as of Q3 2024.
- Raymond James & Associates bought 4,342 Prestige Consumer Healthcare shares in Q3 2024, an estimated $307K.
- Prestige Consumer Healthcare made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1301 holding.
- Raymond James & Associates first reported a position in Prestige Consumer Healthcare in Q4 2014 and has held it in 35 quarters since.
- 328 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.